H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Stealth Biotherapeutics Corp (MITO) today and set a price target of $30. The company’s shares closed yesterday at $12.12, close to its 52-week low of $11.11.
According to TipRanks.com, Chen is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -21.1% and a 35.4% success rate. Chen covers the Healthcare sector, focusing on stocks such as EyePoint Pharmaceuticals Inc, Aerpio Pharmaceuticals Inc, and HTG Molecular Diagnostics.
Currently, the analyst consensus on Stealth Biotherapeutics Corp is a Moderate Buy with an average price target of $29.
See today’s analyst top recommended stocks >>
The company has a one-year high of $20.99 and a one-year low of $11.11. Currently, Stealth Biotherapeutics Corp has an average volume of 5,686.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Stealth BioTherapeutics Corp. is a clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. The company was founded on April 3, 2006 and is headquartered in Newton, MA.
